Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘MEDI9447’

Gardens by the Bay in Singapore

With the abstract titles now available for the World Congress in Lung Cancer (WCLC), it’s time to take a look at what we can expect for the meeting coming up in early September.

In our latest conference Preview, we have highlighted several education sessions to look at, as well as ten key oral presentations to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

New York – at the CRI-CIMT-EATI-AACR international cancer immunotherapy conference (Twitter #CICON16) that’s currently underway, one of the plenary oral presentations and posters that attracted my attention was for CPI-444, a small molecule inhibitor of the adenosine 2 A receptor (A2AR). It is in development by Corvus Pharmaceuticals (NASDAQ: CRVS).

Corvus Pharmaceuticals Logo

Stephen Willingham, PhD a Senior Scientist at Corvus presented data yesterday on CPI-444, “A potent & selective inhibitor of the A2AR that induces antitumor responses alone and in combination with anti PD-L1 in preclinical and biomarker studies.”  

Corvus announced a collaboration with Genentech back in October 2015. A phase 1 trial with CPI-444 alone and in combination with Genentech’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) is now underway.

Targeting the tumor microenvironment to lower the immunosuppressive adenosine and improve checkpoint point effectiveness could be a big win for both Corvus and Genentech if CPI-444 is able to significantly improve the response rates to atezolizumab.

Corvus Senior Scientist Stephen Willingham, PhD and Chief Business Officer Jason Coloma, PhD kindly spoke to BSB about what the data presented in New York means and the company’s clinical development strategy.

Subscribers can login to read more about their insights or you can purchase access.

This content is restricted to subscribers

error: Content is protected !!